12 assets in Malignant Renal Pelvis Neoplasm

Therapeutic assets addressing Malignant Renal Pelvis Neoplasm, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4) Malignant Renal Pelvis Neoplasm	Fred Hutchinson Cancer Center	P2	BB (65)
Pembrolizumab Malignant Renal Pelvis Neoplasm	Fred Hutchinson Cancer Center	P2	B (60)
Atezolizumab Malignant Renal Pelvis Neoplasm	National Cancer Institute (NCI)	P2	B (57)
Apsolol Malignant Renal Pelvis Neoplasm	Emory University	P2	CCC (53)
Eribulin Monomethanesulfonate Malignant Renal Pelvis Neoplasm	National Cancer Institute (NCI)	P2	CCC (53)
Ipilimumab Malignant Renal Pelvis Neoplasm	M.D. Anderson Cancer Center	P2	CCC (53)
Nivolumab Malignant Renal Pelvis Neoplasm	M.D. Anderson Cancer Center	P2	CCC (53)
Relatlimab Malignant Renal Pelvis Neoplasm	M.D. Anderson Cancer Center	P2	CCC (53)
Tocilizumab Malignant Renal Pelvis Neoplasm	M.D. Anderson Cancer Center	P2	CCC (53)
Avelumab Malignant Renal Pelvis Neoplasm	Emory University	P2	CCC (48)
Quemliclustat Malignant Renal Pelvis Neoplasm	Fred Hutchinson Cancer Center	P1/2	CC (47)
Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493 Malignant Renal Pelvis Neoplasm	National Cancer Institute (NCI)	P1	CC (43)